Heling Zhang1, Ye Zhang2. 1. Health Examination Center, The Fourth Hospital of Shijiazhuang Shijiazhuang, Hebei, China. 2. Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University Hebei, China.
Abstract
OBJECTIVE: To investigate the efficacy and safety of olaparib and paclitaxel combined with carboplatin in the treatment of ovarian cancer and its impact on disease control. METHODS: The medical data of 120 patients with ovarian cancer admitted to our hospital from February 2019 to February 2020 were retrospectively analyzed. According to different treatment methods, the enrolled patients were divided into two groups: a control group (n=60) treated with paclitaxel combined with carboplatin, and an experimental group (n=60) additionally treated with olaparib on the basis of the control group. The short-term efficacy, serum levels of carbohydrate antigen 125 (CA125), tumor necrosis factor (TNF-α), interleukin-6 (IL-6), and human epididymis protein 4 (HE4), and the incidence of adverse effects and tumor metastasis were compared between the two groups. RESULTS: There was no difference in the baseline data between the two groups (P>0.05). The objective remission rate (ORR) and disease control rate (DCR) of the experimental group were higher than those of the control group (P<0.05). The experimental group had lower levels of serum CA125, TNF-α, IL-6, and HE4 than the control group after treatment (P<0.05). The two groups showed no significant difference in the incidence of adverse reactions (P>0.05). The one-year follow-up identified a lower tumor metastasis rate in the experimental group compared to the control group (P<0.05). CONCLUSION: Olaparib and paclitaxel combined with carboplatin improve the serum indexes of patients with ovarian cancer, enhance the disease control, and reduce the recurrence rate, without extra toxic side effects. AJTR
OBJECTIVE: To investigate the efficacy and safety of olaparib and paclitaxel combined with carboplatin in the treatment of ovarian cancer and its impact on disease control. METHODS: The medical data of 120 patients with ovarian cancer admitted to our hospital from February 2019 to February 2020 were retrospectively analyzed. According to different treatment methods, the enrolled patients were divided into two groups: a control group (n=60) treated with paclitaxel combined with carboplatin, and an experimental group (n=60) additionally treated with olaparib on the basis of the control group. The short-term efficacy, serum levels of carbohydrate antigen 125 (CA125), tumor necrosis factor (TNF-α), interleukin-6 (IL-6), and human epididymis protein 4 (HE4), and the incidence of adverse effects and tumor metastasis were compared between the two groups. RESULTS: There was no difference in the baseline data between the two groups (P>0.05). The objective remission rate (ORR) and disease control rate (DCR) of the experimental group were higher than those of the control group (P<0.05). The experimental group had lower levels of serum CA125, TNF-α, IL-6, and HE4 than the control group after treatment (P<0.05). The two groups showed no significant difference in the incidence of adverse reactions (P>0.05). The one-year follow-up identified a lower tumor metastasis rate in the experimental group compared to the control group (P<0.05). CONCLUSION: Olaparib and paclitaxel combined with carboplatin improve the serum indexes of patients with ovarian cancer, enhance the disease control, and reduce the recurrence rate, without extra toxic side effects. AJTR
Authors: Gizem Oner; Sevilay Altintas; Zafer Canturk; Wiebren Tjalma; Yannick Verhoeven; Christophe Van Berckelaer; Zwi Berneman; Marc Peeters; Patrick Pauwels; Peter A van Dam Journal: Breast J Date: 2019-12-04 Impact factor: 2.431
Authors: Ignace Vergote; Deborah Armstrong; Giovanni Scambia; Michael Teneriello; Jalid Sehouli; Charles Schweizer; Susan C Weil; Aristotelis Bamias; Keiichi Fujiwara; Kazunori Ochiai; Christopher Poole; Vera Gorbunova; Wenquan Wang; Daniel O'Shannessy; Thomas J Herzog Journal: J Clin Oncol Date: 2016-03-21 Impact factor: 44.544
Authors: Anna P Sokolenko; Tatiana V Gorodnova; Ilya V Bizin; Ekaterina Sh Kuligina; Khristina B Kotiv; Alexandr A Romanko; Tatiana I Ermachenkova; Alexandr O Ivantsov; Elena V Preobrazhenskaya; Tatiana N Sokolova; Robert V Broyde; Evgeny N Imyanitov Journal: Cancer Chemother Pharmacol Date: 2021-06-02 Impact factor: 3.333
Authors: Michael C J Quinn; Karen McCue; Stuart MacGregor; Georgia Chenevix-Trench; Wei Shi; Sharon E Johnatty; Jonathan Beesley; Andrew Civitarese; Tracy A O'Mara; Dylan M Glubb; Jonathan P Tyrer; Sebastian M Armasu; Jue-Sheng Ong; Puya Gharahkhani; Yi Lu; Bo Gao; Ann-Marie Patch; Peter A Fasching; Matthias W Beckmann; Diether Lambrechts; Ignace Vergote; Digna R Velez Edwards; Alicia Beeghly-Fadiel; Javier Benitez; Maria J Garcia; Marc T Goodman; Thilo Dörk; Matthias Dürst; Francesmary Modugno; Kirsten Moysich; Andreas du Bois; Jacobus Pfisterer; Klaus Bauman; Beth Y Karlan; Jenny Lester; Julie M Cunningham; Melissa C Larson; Bryan M McCauley; Susanne K Kjaer; Allan Jensen; Claus K Hogdall; Estrid Hogdall; Joellen M Schildkraut; Marjorie J Riggan; Andrew Berchuck; Daniel W Cramer; Kathryn L Terry; Line Bjorge; Penelope M Webb; Michael Friedlander; Tanja Pejovic; Melissa Moffitt; Rosalind Glasspool; Taymaa May; Gabrielle E V Ene; David G Huntsman; Michelle Woo; Michael E Carney; Samantha Hinsley; Florian Heitz; Sian Fereday; Catherine J Kennedy; Stacey L Edwards; Stacey J Winham; Anna deFazio; Paul D P Pharoah; Ellen L Goode Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-06-23 Impact factor: 4.090